Clinical Trials Browser

Phase 1/2 × darolutamide × 90 days × Clear all

NCT07190300 2026-06-03

TulmiSTAR-02

Phase 1/2 Recruiting

Bulbo-Spinal Atrophy, X-Linked

NCT05367440 2026-06-01

PETRANHA

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant